Dysregulation of MMSET through chromosomal translocations, mutations, or overexpression is a hallmark of several cancers, particularly the t(4;14) translocation, which occurs in 10%‐15% of MM and leads to MMSET overexpression, an established contributor to chemoresistance and poor prognosis [29]. This evidence concerns the gene NSD2 and Miyoshi myopathy.